Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

NCT02244255 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02244255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
August 31, 1998
Completion date
Not reported
Enrollment
1,993 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic hyperplasia